In a report issued on August 10, David Buck from B.Riley FBR reiterated a Buy rating on Corcept Therapeutics Inc (NASDAQ: CORT), with a price target of $22. The company’s shares closed on Friday at $13.26, close to its 52-week low of $11.55.
According to TipRanks.com, Buck is a 4-star analyst with an average return of 13.7% and a 72.2% success rate. Buck covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Supernus Pharmaceuticals, and Amag Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Corcept Therapeutics Inc with a $19.33 average price target, a 45.8% upside from current levels. In a report issued on August 9, Seaport Global also reiterated a Buy rating on the stock with a $25 price target.
The company has a one-year high of $25.96 and a one-year low of $11.55. Currently, Corcept Therapeutics Inc has an average volume of 1.28M.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock. Last month, James N. Wilson, a Director at CORT bought 10,000 shares for a total of $23,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K.